Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 11/20 | 1.00 |
| ▸ | SRC | P12931 | 5/20 | 1.00 |
| ▸ | INSR | P06213 | 4/20 | 1.00 |
| ▸ | IGF1R | P08069 | 4/20 | 1.00 |
| ▸ | EPHB4 | P54760 | 2/20 | 1.00 |
| ▸ | EGFR | P00533 | 11/20 | 0.85 |
| ▸ | KDR | P35968 | 9/20 | 0.85 |
| ▸ | TEK | Q02763 | 5/20 | 0.85 |
| ▸ | FLT4 | P35916 | 4/20 | 0.85 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.85 |
| ▸ | AURKB | Q96GD4 | 10/20 | 0.62 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.51 |
| ▸ | GSK3B | P49841 | 1/20 | 0.51 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.50 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5262588 | 0.92 | AURKA (1.00) | AURKASRCINSRIGF1REPHB4 | |
| SCHEMBL5260575 | 0.85 | INSR (1.00) | AURKASRCINSRIGF1REPHB4 | |
| SCHEMBL5256953 | 0.77 | EGFR (1.00) | AURKASRCINSRIGF1REPHB4 | |
| SCHEMBL5263878 | 0.76 | INSR (0.82) | AURKASRCINSRIGF1REPHB4 | |
| SCHEMBL5260098 | 0.75 | AURKA (1.00) | AURKASRCINSRIGF1REPHB4 | |
| SCHEMBL5262114 | 0.74 | AURKA (1.00) | AURKASRCINSRIGF1REPHB4 | |
| SCHEMBL14621122 | 0.72 | EGFR (0.66) | AURKASRCINSRIGF1REPHB4 | |
| SCHEMBL5260400 | 0.70 | EGFR (0.85) | AURKASRCINSRIGF1REPHB4 | |
| SCHEMBL12430723 | 0.70 | AURKA (0.69) | AURKASRCINSRIGF1REPHB4 | |
| SCHEMBL14602748 | 0.70 | AURKA (1.00) | AURKASRCINSRIGF1REPHB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007009524-A1 | 2-ARYLBENZOTHIAZOLES AND USES THEREOF | 4SC AG (DE) | 2007-01-25 | — | — | WO | disclosed |
| US-20070021446-A1 | 2-arylbenzothiazole analogues and uses thereof | 4SC AG (DE) | 2007-01-25 | — | — | US | disclosed |
| US-20070021446-A1 | 2-arylbenzothiazole analogues and uses thereof | 4SC AG (DE) | 2007-01-25 | — | — | US | disclosed |
| EP-1746096-A1 | 2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer | 4SC AG (DE) | 2007-01-24 | — | — | EP | disclosed |
| EP-1746096-A1 | 2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer | 4SC AG (DE) | 2007-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021446-A1 | 2-arylbenzothiazole analogues and uses thereof | NR2E1, NR2E3, NR0B2 | AURKA 493/4885SRC 382/4885INSR 481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.